Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 17:11:2021-11-5.
doi: 10.7573/dic.2021-11-5. eCollection 2022.

Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study

Cristóbal Morales  1   2 , Juan Francisco Merino-Torres  3 , Paloma Moreno-Moreno  4 , María Lainez  5 , Iñigo Tejado  6 , Alfredo Yoldi  7 , Sonsoles Gutiérrez Medina  8 , Alfonso Soto  9 , Manuel A Botana  10 , Virginia Bellido  11 , Irene Caballero  1   2
Affiliations

Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study

Cristóbal Morales et al. Drugs Context. .

Abstract

Background: This study aims to evaluate dapagliflozin in patients with type 2 diabetes (T2D) in clinical practice in Spain.

Methods: This is a retrospective study including adults with T2D under stable antidiabetic therapy, with either dapagliflozin or sitagliptin ≥6 months, before inclusion. Data about the effectiveness and safety of dapagliflozin are presented.

Results: A total of 594 patients (61.8±9.9 years, 21.7% cardiovascular disease) were included. After 6 months, HbA1c, weight, blood pressure, urine albumin-to-creatinine ratio and uric acid significantly decreased (1.63%, 2.88 kg, 4.82/2.70 mmHg, -17.38 mg/g and -0.30 mg/dL, respectively), whereas glomerular filtration rate and haematocrit significantly increased (3.72 mL/min/1.73 m2 and 1.8%, respectively). No cases of hypoglycaemia, diabetic ketoacidosis, Fournier gangrene, fractures or amputations were reported.

Conclusion: Thus, dapagliflozin provides a comprehensive cardiometabolic protection in patients with T2D.

Keywords: HbA1c; clinical practice; dapagliflozin; diabetes; weight.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: This work was supported by AstraZeneca. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2022/01/dic.2021-11-5-COI.pdf

Figures

Figure 1
Figure 1. Previous antihyperglycaemic treatments
DPP4, dipeptidyl peptidase 4; GLP1, glucagon-like peptide 1; SGLT2, sodium-glucose cotransporter 2.
Figure 2
Figure 2
Proportion of patients reaching weight reduction ≥1.5 kg, glycosylated haemoglobin (HbA1c) ≥0.5%, and the composite goal of reducing weight ≥1.5 kg and HbA1c ≥0.5% (primary endpoint) after 6 months of treatment with dapagliflozin.
See this image and copyright information in PMC

References

    1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. doi: 10.1038/nrendo.2017.151. - DOI - PubMed
    1. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. 2019. [Accessed November 16, 2021]. http://www.diabetesatlas.org .
    1. Rojo-Martínez G, Valdés S, Soriguer F, et al. Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study. Sci Rep. 2020;10(1):2765. doi: 10.1038/s41598-020-59643-7. - DOI - PMC - PubMed
    1. Mohammedi K, Woodward M, Marre M, et al. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. Cardiovasc Diabetol. 2017;16(1):95. doi: 10.1186/s12933-017-0574-y. - DOI - PMC - PubMed
    1. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. doi: 10.1093/eurheartj/ehz486. - DOI - PubMed